JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals’ Ziihera received FDA approval as first-line treatment for HER2-positive GEA, expanding the company’s addressable market. The approval is supported by strong clinical outcomes, with reported progression-free and survival benefits. This is a meaningful regulatory milestone likely to improve forward revenue expectations and investor sentiment.